Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B

Journal of Medical Virology

Volumn 66, Issue 4, 2002, Pages 452-460

  Ross, R Stefan ^a   Viazov, Sergei ^a   Roggendorf, Michael ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Chronic hepatitis B; ELISPOT; Interleukin 2; Lamivudine; T and B cells; Therapeutic vaccine

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HLA A2 ANTIGEN; IMMUNOMODULATING AGENT; INTERLEUKIN 2; LAMIVUDINE; RECOMBINANT INTERLEUKIN 2; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ANTIBODY PRODUCTION; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOSTIMULATION; SEROLOGY; T LYMPHOCYTE ACTIVATION; VACCINATION; VIRUS CARRIER; VIRUS DETECTION; VIRUS NEUTRALIZATION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INJECTIONS, INTRADERMAL; INTERLEUKIN-2; LAMIVUDINE; LYMPHOCYTE ACTIVATION; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VACCINATION; VACCINES, SYNTHETIC;

HEPATITIS B VIRUS;

EID: 0036200712     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.2165     Document Type: Article

References (36)

1. Mechanism of action of vaccine therapy in murine hepatitis B virus carriers: Vaccine-induced activation of antigen presenting dendritic cells
2. Th1-Th2: Reliable paradigm or dangerous dogma?
3. Double-blind randomized controlled trial of interleukin-2 treatment of chronic hepatitis B
4. Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes
5. Regulation of the neutralizing anti-hepatitis B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus (HBV) infection
6. Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: Stimulation of the in vitro antibody response by interferon gamma
7. Reduced hepatitis B virus surface antigen-specific Th1 helper cell frequency of chronic HBV carriers is associated with a failure to produce antigen-specific antibodies in the Trimera Mouse
8. Exogenous hepatitis B surface antigen particles processed by dendritic cells or macrophages prime murine MHC class I-restricted cytotoxic T lymphocytes in vivo
9. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B
10. Presentation of viral antigen controlled by a gene in the major histocompatibility complex
11. Hepatitis B virus immunopathogenesis
12. Specific vaccine therapy in chronic hepatitis B: Induction of T cell proliferative responses specific for envelope antigens
13. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy
14. Anatomical environment as determinant in viral immunity
15. Intrahepatic, nucleocapsid antigen-specific T cells in chronic active hepatitis B
16. Biological standards for hepatitis B virus assays
17. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B
18. Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection
19. A one-year trial of lamivudine for chronic hepatitis B
20. Low frequency of cytotoxic liver-infiltrating T lymphocytes specific for endogenous processed surface and core proteins in chronic hepatitis B
21. Proliferative response of CD4+ T cells and hepatitis B virus clearance in chronic hepatitis with or without hepatitis B e-minus hepatitis B virus mutants
22. Quantitative and functional analysis of core specific T helper cell and CTL activities in acute and chronic hepatitis B
23. Direct ex vivo analysis of hepatitis B virus specific CD8+ T cells associated with the control of infection
24. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice
25. HLA-A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection
26. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen
27. Immune effects of alfa-Interferon in chronic liver disease
28. Immunotherapy of chronic hepatitis B by anti HBV vaccine
29. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen
30. Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: Implication for the pathogenesis of HBV-induced hepatitis
31. Induction of tolerance by IL-10 treated dendritic cells
32. Interleukin-10 treated human dendritic cells induce a melanoma-antigen specific anergy in CD8+ T cells resulting in a failure to lyse tumor cells
33. Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects
34. Survival in chronic hepatitis B: An analysis of 379 patients
35. HIV-1 specific CTL responses primed in vitro by blood derived dendritic cells and Th1-biasing cytokines
36. MHC-restricted cytotoxic T cells. Studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction specificity